ArticleFrontiers in immunology2022
The NLRP3 Inflammasome Inhibitor Dapansutrile Attenuates Cyclophosphamide-Induced Interstitial Cystitis.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Neuroprotective effects of dapansutrile in rotenone-induced parkinsonism: targeting NLRP3/caspase-1, NF-κB, Nrf2/HO-1, and PINK1/Parkin pathways.Inflammopharmacology · 2026Article
- Fucoidan from Fucus Vesiculosus Alleviates Interstitial Cystitis by Suppressing the AKT/NLRP3 Inflammasome Axis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Targeting Inflammation in Atherosclerosis: Mechanistic Rationale, Clinical Trials, and Regulatory Considerations.Reviews in cardiovascular medicine · 2026Review
- Molecular Signatures of Bladder Pain Syndrome: A Systematic Review Towards Phenotype-Informed Diagnostics.International urogynecology journal · 2026Review
- Dapansutrile mitigates methotrexate-induced hepatotoxicity in rats: roles of inflammation, oxidative stress, pyroptosis, and autophagy.Frontiers in pharmacology · 2026Article
- Shaping the future of abdominal and pelvic pain research with novel scientific and technological advances.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Signaling pathways related to interstitial cystitis.Frontiers in immunology · 2026Review
- TP63 regulates pyroptosis via NF-κB/NLRP3/caspase-1 signaling in interstitial cystitis: insights from single-cell sequencing.Open medicine (Warsaw, Poland) · 2026Article
- Mitochondrial damage causes inflammation via cGAS-STING signaling in ketamine-induced cystitis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives.Frontiers in pharmacology · 2025Review
- Doxorubicin-induced nephrotoxicity: the protective role of a standardized ethanolic extract ofFrontiers in pharmacology · 2025Article
- Interrelation of Natural Polyphenol and Fibrosis in Diabetic Nephropathy.Molecules (Basel, Switzerland) · 2024Review
- Hispidulin targets PTGS2 to improve cyclophosphamide-induced cystitis by suppressing NLRP3 inflammasome.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Temporally complex inflammatory networks in an animal model reveal signatures for interstitial cystitis and bladder pain syndrome phenotype.Neurourology and urodynamics · 2023Article
- Piceatannol induces regulatory T cells and modulates the inflammatory response and adipogenesis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Emodin inhibits bladder inflammation and fibrosis in mice with interstitial cystitis by regulating JMJD3.Acta cirurgica brasileira · 2023Article
- TRPV4 activation prevents lipopolysaccharide-induced painful bladder hypersensitivity in rats by regulating immune pathways.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Interstitial cystitis (IC)/bladder pain syndrome (BPS), hereafter referred together as IC, is a clinical syndrome characterized by sterile inflammation in the bladder. While the etiology and pathophysiology of IC remain unclear, it may involve autoimmunity in light of the significant role played by the NLRP3 inflammasome. However, the effect of NLRP3 inhibitors including dapansutrile (Dap) on IC had not been explored previously. Here, we investigated the effect of Dap in the cyclophosphamide (CYP)-induced experimental mouse model of IC, which results in functional and histological alterations confined to the urinary bladder (UB) comparable to that of clinical IC. CYP-induced mice treated with Dap exhibited improved UB pathology and reductions in inflammation scores and the frequency and the number of mast cells and neutrophils, relative to mice that received CYP alone. Dap- and CYP-treated mice also exhibited infiltration of T cells in the spleen and iliac lymph nodes (ILNs) and a concurrent significant decrease (p<0.01) in CXCR3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.